Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

Saved in:
Bibliographic Details
Title: Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.
Authors: Sjoquist KM; NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia. Katrin.sjoquist@sydney.edu.au.; Cancer Care Centre, St George Hospital, Kogarah, Australia. Katrin.sjoquist@sydney.edu.au.; Australia New Zealand Gynaecological Oncology Group, Sydney, Australia. Katrin.sjoquist@sydney.edu.au., Dobrovic A; Department of Surgery, The University of Melbourne, Parkville, Australia., Robledo KP; NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia., Nesic K; Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.; Department of Medical Biology, University of Melbourne, Melbourne, Australia., Baron-Hay S; Royal North Shore Hospital, Sydney, Australia.; Breast Cancer Trials ANZ, Newcastle, Australia., Ananda S; Australia New Zealand Gynaecological Oncology Group, Sydney, Australia.; Peter MacCallum Cancer Centre, Melbourne, Australia., McCarthy N; Breast Cancer Trials ANZ, Newcastle, Australia.; ICON Cancer Centre Wesley Auchenflower, Auchenflower, Australia., Goh J; Australia New Zealand Gynaecological Oncology Group, Sydney, Australia.; Royal Brisbane & Women's Hospital, Herston, Australia., Steer C; Border Medical Oncology Research Unit, Albury Wodonga Regional Cancer Centre, Albury, Australia.; UNSW School of Clinical Medicine, Rural Clinical Campus, Albury, Australia., Murray N; Breast Cancer Trials ANZ, Newcastle, Australia.; Royal Adelaide Hospital, Adelaide, South Australia., Yip S; NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia., Mileshkin LR; Australia New Zealand Gynaecological Oncology Group, Sydney, Australia.; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia., Fink JL; XING Genomic Services, Brisbane, Australia., Chang G; NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia., Bailey L; NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia., Lee Y; NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia., Zebic DS; NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia.; Department of Medical Oncology, Wollongong Hospital, Wollongong, NSW, Australia., Kariyawasam UGIU; Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.; Department of Medical Biology, University of Melbourne, Melbourne, Australia., Shield-Artin K; Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.; Department of Medical Biology, University of Melbourne, Melbourne, Australia., Jarratt A; Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.; Department of Medical Biology, University of Melbourne, Melbourne, Australia., Bedő J; Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.; Department of Medical Biology, University of Melbourne, Melbourne, Australia., Papenfuss AT; Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.; Department of Medical Biology, University of Melbourne, Melbourne, Australia., Kondrashova O; Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.; QIMR Berghofer Medical Research Institute, Brisbane, Australia., Wakefield MJ; Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.; Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne, Melbourne, Australia., Vandenberg CJ; Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.; Department of Medical Biology, University of Melbourne, Melbourne, Australia., Stockler MR; NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia., Scott CL; Australia New Zealand Gynaecological Oncology Group, Sydney, Australia.; Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.; Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne, Melbourne, Australia., Waring PM; XING Genomic Services, Brisbane, Australia.; Department of Translational Pathology, AstraZeneca, Cambridge, UK.
Source: British journal of cancer [Br J Cancer] 2026 Jul 08. Date of Electronic Publication: 2026 Jul 08.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1532-1827
DOI:10.1038/s41416-026-03535-6